These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 34285711)
41. Term Human Placental Trophoblasts Express SARS-CoV-2 Entry Factors ACE2, TMPRSS2, and Furin. Ouyang Y; Bagalkot T; Fitzgerald W; Sadovsky E; Chu T; Martínez-Marchal A; Brieño-Enríquez M; Su EJ; Margolis L; Sorkin A; Sadovsky Y mSphere; 2021 Apr; 6(2):. PubMed ID: 33853873 [TBL] [Abstract][Full Text] [Related]
42. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2). Xiang Y; Wang M; Chen H; Chen L Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003 [TBL] [Abstract][Full Text] [Related]
43. Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. Amirfakhryan H; Safari F Hellenic J Cardiol; 2021; 62(1):13-23. PubMed ID: 32522617 [TBL] [Abstract][Full Text] [Related]
44. Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions. Wakabayashi M; Pawankar R; Narazaki H; Ueda T; Itabashi T Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):1-7. PubMed ID: 33186186 [TBL] [Abstract][Full Text] [Related]
45. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. Yamaguchi T; Hoshizaki M; Minato T; Nirasawa S; Asaka MN; Niiyama M; Imai M; Uda A; Chan JF; Takahashi S; An J; Saku A; Nukiwa R; Utsumi D; Kiso M; Yasuhara A; Poon VK; Chan CC; Fujino Y; Motoyama S; Nagata S; Penninger JM; Kamada H; Yuen KY; Kamitani W; Maeda K; Kawaoka Y; Yasutomi Y; Imai Y; Kuba K Nat Commun; 2021 Nov; 12(1):6791. PubMed ID: 34815389 [TBL] [Abstract][Full Text] [Related]
46. An update on ACE2 amplification and its therapeutic potential. Marquez A; Wysocki J; Pandit J; Batlle D Acta Physiol (Oxf); 2021 Jan; 231(1):e13513. PubMed ID: 32469114 [TBL] [Abstract][Full Text] [Related]
47. SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2. Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T Cells; 2021 Jun; 10(6):. PubMed ID: 34201214 [TBL] [Abstract][Full Text] [Related]
48. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. Qu L; Chen C; Yin T; Fang Q; Hong Z; Zhou R; Tang H; Dong H Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768911 [TBL] [Abstract][Full Text] [Related]
49. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease. Lebek S; Tafelmeier M; Messmann R; Provaznik Z; Schmid C; Maier LS; Birner C; Arzt M; Wagner S Eur J Heart Fail; 2020 Dec; 22(12):2248-2257. PubMed ID: 33017071 [TBL] [Abstract][Full Text] [Related]
50. Physiological implications of COVID-19 in reproduction: angiotensin-converting enzyme 2 a key player. Sharma GT; Chandra V; Mankuzhy P; Thirupathi Y; Swain DK; Pillai H; Patel SK; Pathak M; Guttula S Reprod Fertil Dev; 2021 Apr; 33(6):381-391. PubMed ID: 33731252 [TBL] [Abstract][Full Text] [Related]
51. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
52. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
53. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370 [TBL] [Abstract][Full Text] [Related]
54. Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients. Rahman MM; Hasan M; Ahmed A Rev Med Virol; 2021 Sep; 31(5):1-12. PubMed ID: 33426683 [TBL] [Abstract][Full Text] [Related]
55. Advances in Targeting ACE2 for Developing COVID-19 Therapeutics. Suvarnapathaki S; Chauhan D; Nguyen A; Ramalingam M; Camci-Unal G Ann Biomed Eng; 2022 Dec; 50(12):1734-1749. PubMed ID: 36261668 [TBL] [Abstract][Full Text] [Related]
56. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. Lores E; Wysocki J; Batlle D Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725 [TBL] [Abstract][Full Text] [Related]
57. ACE2 role in SARS-CoV-2 infectivity and Covid-19 severity. Azizan E; Brown M Malays J Pathol; 2020 Dec; 42(3):363-367. PubMed ID: 33361716 [TBL] [Abstract][Full Text] [Related]
58. Repositioning of histamine H Ge S; Wang X; Hou Y; Lv Y; Wang C; He H Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607 [TBL] [Abstract][Full Text] [Related]
59. ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders. Cao X; Song LN; Yang JK Clin Sci (Lond); 2021 Feb; 135(3):535-554. PubMed ID: 33533405 [TBL] [Abstract][Full Text] [Related]
60. Expression of ACE2 and TMPRSS2 Proteins in the Upper and Lower Aerodigestive Tracts of Rats: Implications on COVID 19 Infections. Sato T; Ueha R; Goto T; Yamauchi A; Kondo K; Yamasoba T Laryngoscope; 2021 Mar; 131(3):E932-E939. PubMed ID: 32940922 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]